Archives of Virology

, Volume 141, Issue 10, pp 1921–1932 | Cite as

Selection of hepatitis C virus quasispecies during interferon treatment

  • I. Sakuma
  • N. Enomoto
  • M. Kurosaki
  • F. Marumo
  • C. Sato
Original Papers

Summary

Preliminary studies have shown that hepatitis C virus (HCV) quasi-species populations after interferon therapy are different from those before interferon, suggesting that selection of HCV quasispecies occurs during IFN treatment. To confirm this, fluctuations of HCV quasispecies populations were investigated by single strand conformation polymorphism analysis in eight patients who remained viremic during interferon treatment. In all patients, HCV quasispecies populations changed in 1 to 4 months after the start of interferon therapy. In seven patients, a minor population of HCV quasispecies that was present before the interferon therapy was selected and became predominant during the therapy, whereas the abundance of the other quasispecies was reduced. In the other patient, new HCV quasispecies that had not been detected before interferon therapy appeared and replaced the pretreatment HCV. In contrast, no significant changes were observed during the pretreatment period in these patients. In two patients, deduced amino acid sequences of the hypervariable region were identical despite the difference in nucleotide sequences between interferon-sensitive and interferon-resistant HCV. Thus, selection of HCV quasispecies occurs during interferon treatment and immune responses to the hypervariable region may not be the determining factor of the selection.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HJ, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL (1989) Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis International Therapy Group. N Engl J Med 321: 1501–1506Google Scholar
  2. 2.
    Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, Cales P, Couzigou P, Benhamou JP (1991) Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 13: 393–397Google Scholar
  3. 3.
    Takada N, Takase S, Enomoto N, Takada A, Date T (1992) Clinical backgrounds of the patients having different types of hepatitis C virus genomes. J Hepatol 14: 35–40Google Scholar
  4. 4.
    Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, Shibata M, Morishita T (1992) Detection of hepatitis C virus by polymerase chain reaction to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 16: 293–299Google Scholar
  5. 5.
    Kanai K, Kako M, Okamoto H (1992) HCV genotypes in chronic hepatitis C and response to interferon. Lancet 339: 1543Google Scholar
  6. 6.
    Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Hiromitsu K (1994) Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 19: 1088–1094Google Scholar
  7. 7.
    Sieck JO, Ellis ME, Alfurayh O, Ali MA, Ali HA, Ayub A, al-Fadda M, Zafar M, Halim M, Bernvil M (1993) Histologically advanced chronic hepatitis C treated with recombinant alpha-interferon: a randomized placebo-controlled double-blind cross-over study. J Hepatol 19: 418–423Google Scholar
  8. 8.
    Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC (1993) Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341: 1501–1504Google Scholar
  9. 9.
    Hino K, Sainokami S, Shimoda K, Iino S, Wang Y, Okamoto H, Miyakawa Y, Mayumi M (1994) Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 42: 299–305Google Scholar
  10. 10.
    Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, Fusamoto H, Kamada T (1994) Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 9: 977–982Google Scholar
  11. 11.
    Holland JJ, De La Torre JC, Steinhauer DA (1992) RNA virus populations as quasispecies. Curr Top Microbiol Immunol 176: 1–20Google Scholar
  12. 12.
    Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, Gomez J (1992) Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 66: 3225–3229Google Scholar
  13. 13.
    Kurosaki M, Enomoto N, Marumo F, Sato C (1994) Evolution and selection of hepatitis C virus variants in patients with chronic hepatitis C. Virology 205: 161–169Google Scholar
  14. 14.
    Enomoto N, Kurosaki M, Marumo F, Sato C (1994) Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single strand conformation polymorphism analysis. J Gen Virol 75: 1361–1369Google Scholar
  15. 15.
    Kurosaki M, Enomoto N, Tanaka Y, Hoshino Y, Izumi N, Marumo F, Sato C (1995) Detection and analysis of replicating hepatitis C virus quasispecies in hepatocellular carcinoma tissue. J Hepatol 22: 527–535Google Scholar
  16. 16.
    Kato N, Sekiya H, Ootsuyma Y, Nakazawa T, Hijikata M, Ohkoshi S, Shimotono K (1993) Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol 67: 3923–3030Google Scholar
  17. 17.
    Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, Crawford K, Bonino F, Saracco G, Choo QL, Houghton M (1991) Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 180: 842–848Google Scholar
  18. 18.
    Kumar U, Monjardino J, Thomas HC (1994) Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology 106: 1072–1075Google Scholar
  19. 19.
    Enomoto N, Sato C, Kurosaki M, Marumo F (1994) Hepatitis C virus after interferon treatment has the variation in the hypervariable region of envelope 2 gene. J Hepatol 20: 252–261Google Scholar
  20. 20.
    Higashi Y, Kakumu S, Yoshioka K, Wakita T, Mizokami M, Ohba K, Ito Y, Ishikawa T, Takayanagi M, Nagai Y (1993) Dynamics of genome change in the E2/NS1 region of hepatitis C virus in vivo. Virology 197: 659–668Google Scholar
  21. 21.
    Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S (1992) The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16: 619–624Google Scholar
  22. 22.
    Orita M, Suzuki Y, Sekiya T, Hayashi K (1989) Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874–879Google Scholar
  23. 23.
    Yap EP-H, Lo Y-MD, Cooper K, Fleming KA, McGee JO (1992) Exclusion of false-positive PCR viral diagnosis by single-strand conformation polymorphism. Lancet 340: 736Google Scholar
  24. 24.
    Okamoto H, Okada S, Sugiyama Y, Tanaka T, Sugai Y, Akahane Y, Machida A, Mishiro S, Yoshizawa H, Miyakawa Y (1990) Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Jpn J Exp Med 60: 215–222Google Scholar
  25. 25.
    Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, Chan SW, Chayama K, Chen DS, Choo QL, Colombo M, Cuypers T, Date T, Dusheiko GM, Esteban JI, Fay O, Hadziyanni's SJ, Han J, Hatzakis A, Holmes EC, Hotta H, Houghton M, Irvine B (1994) A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19: 1321–1324Google Scholar
  26. 26.
    Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y, Mayumi M (1992) Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 73: 673–679Google Scholar
  27. 27.
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ (1994) Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19: 1513–1520Google Scholar
  28. 28.
    Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156–159Google Scholar
  29. 29.
    Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA (1988) Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerese. Science 239: 487–491Google Scholar
  30. 30.
    Gyllensten UB, Erlich HA (1988) Generation of single-stranded DNA by the plymerase chain reaction and its application to direct sequencing of the HLA-DQA locus. Proc Natl Acad Sci USA 85: 7652–7656Google Scholar
  31. 31.
    Yap E-PH, McGee JO (1992) Nonisotopic SSCP detection in PCR products by ethidium bromide staining. Trends Genet 8: 49Google Scholar
  32. 32.
    Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K (1990) Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 87: 9254–9528Google Scholar
  33. 33.
    Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C (1995) Comparison of full-length sequences of interferon sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 96: 224–230Google Scholar
  34. 34.
    Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334: 77–81Google Scholar
  35. 35.
    Sekiya H, Kato N, Ootsuyama Y, Nakazawa T, Yamauchi K, Shimotohno K (1994) Genetic alterations of the putative envelope proteins encoding region of the hepatitis C virus in the progression to relapsed phase from acute hepatitis: humoral immune response to hypervariable region 1. Int J Cancer 57: 664–670Google Scholar
  36. 36.
    Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, Bonino F, Crawford K, Marion CD, Crawford KA, Brunetto M, Barr PJ, Miyamura T, McHutchinson J, Houghton M (1992) Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci USA 89: 3468–3472Google Scholar
  37. 37.
    Kumar U, Brown J, Monjardino J, Thomas HC (1993) Sequence variation in the large envelope glycoprotein (E2/NS1) of hepatitis C virus during chronic infection. J Infect Dis 167: 726–730Google Scholar
  38. 38.
    Kurosaki M, Enomoto N, Marumo F, Sato C (1993) Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection. Hepatology 18: 1293–1299Google Scholar
  39. 39.
    Nakazawa T, Kato N, Ootsuyama Y, Sekiya H, Fujioka T, Shibuya A, Shimotohno K (1994) Genetic alteration in the hepatitis C virus hypervariable region obtained from an asymptomatic carrier. Int J Cancer 56: 204–207Google Scholar
  40. 40.
    Okamoto H, Kojima M, Okada S, Yoshizawa H, Iizuka H, Tanaka T, Muchmore EE, Peterson DA, Ito Y, Mishiro S (1992) Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 190: 894–899Google Scholar
  41. 41.
    Ogata N, Alter HJ, Miller RH, Purcell RH (1991) Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 88: 3392–3396Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • I. Sakuma
    • 1
  • N. Enomoto
    • 1
  • M. Kurosaki
    • 1
  • F. Marumo
    • 1
  • C. Sato
    • 1
    • 2
  1. 1.Second Department of Internal Medicine, Faculty of MedicineTokyo Medical and Dental UniversityTokyoJapan
  2. 2.Division of Health Science, Faculty of MedicineTokyo Medical and Dental UniversityTokyoJapan

Personalised recommendations